Long-Term Response to Camrelizumab in a Pretreated Metastatic Mixed Testicular Germ-Cell Tumor Patient with Co-Mutations in DNA Damage-Repair Genes

• DOI: 10.2217/imt-2021-0259
• Publication Date: 2023-01-17T10:39:12Z
• Authors: Hui Zhang; Da Jiang; Erhong Meng; Meng Zhao; Beifang Niu
• Keywords: PMS2; MSH6; Immune checkpoint

Little information is available regarding the therapeutic efficacy of immune checkpoint inhibitors and prediction DNA damage-repair (DDR) genes in mixed testicular germ-cell tumors (TGCTs). Here we report a pretreated patient with metastatic TGCT harboring variations three important DDR - BRCA2, MSH6 PMS2 identified by next-generation sequencing using plasma-based circulating tumor DNA. He obtained stable clinical benefit from PD-1 blockade. At latest follow-up, he had progression-free survival more than 28 months survived 6.75 years since diagnosis. To our knowledge, this case first long-term outcome inhibitor therapy co-mutations genes.